News | August 02, 2021
Ajanta Pharma aims to file 10-12 ANDAs per annum
India business is growing as per projections; whereas US business will bounce back soon.
India business is growing as per projections; whereas US business will bounce back soon.
It posted net profit of Rs.147.76 crores for the period ended June 30, 2020.
The companyreported total income of Rs.2915.67 crores during the 12 months period ended March 31, 2021
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
A pharma industry veteran with over three decades of experience in domestic as well as international markets
ICICI Direct gives a preview on the earnings narrative for Q3FY22
Subscribe To Our Newsletter & Stay Updated
